Result: Five PHPT-4 subjects and eight PHPT-2 controls had minor NNRTI mutations in postpartum samples (V179D, K101E, V106I, or V90I).
Table: V179D
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
PMID: 20462946
2010
The Journal of antimicrobial chemotherapy
Method: The complete list of etravirine RAMs was defined as V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L.
Method: We performed multidimensional scaling on the pairwise association data using a matrix D of dissimilarity coefficients (JD = 1 - J, where J is the Jaccard similarity coefficient) for the 22 mutations found in the significantly positively associated pairs (corrected P < 0.05): A98G, L100I,
Table: V179D
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.
Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.
PMID: 20535242
2010
Letters in drug design & discovery
Introduction: Mutations associated with resistance to NNRTIs include L100I, K101E, K103N, V106A, V108I, V179D, Y181C, Y188C/L/H, G190A/E/S, M230L, P236L and Y318F.
Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
PMID: 20805392
2010
Antimicrobial agents and chemotherapy
Abstract: In subtype B viruses, on the other hand, known NNRTI-associated mutations (e.g., Y181C, P236L, L100I, V179D, and K103N) were selected by the NNRTIs.
[Prevalence of primary antiretroviral resistance among HIV infected patients in Chile].
Abstract: Point mutations for non nucleoside reverse transcriptase inhibitors (NNRTI) were detected in 4.1% of cases (K103N in 1 patient, V179D in 2 patients), for nucleoside reverse transcriptase inhibitors (NRTI) in 8.1% of cases (T215S in 1 patient, V118I in 4 patients, M41L in 1 patient) and for protease inhibitors (PI) in 1.3% of cases.
Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.
Abstract: These included V90I, A98G, L100I, K1O1E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
PMID: 19552593
2009
AIDS research and human retroviruses
Introduction: Eight infants had mutations detected by ViroSeq [Y181C (n = 4), K103N (n = 1), V106M (n = 1), Y188C (n = 1), and V179D+K103R (n = 1)], and four infants had resistance detected by LigAmp only (all with Y181C, at 1.2%, 1.4%, 3.5%, and 7.8%; one infant also had G190A at 1.9%).
Table: V179D
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Method: Etravirine-resistance mutations were defined as mutations associated in the DUET studies with a decreased virological response to etravirine: V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, and M230L.
Method: The mutations V90I, A98G, V106I, E138A, and V179D/T were considered to be less important indicators of etravirine re
HIV mutation literature information.
PMID: 
2010
Clinical infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT